BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, announced that, effective immediately, Anika’s Board of Directors has appointed Susan Vogt as an independent director.
Ms. Vogt most recently served as Chief Executive Officer and Director of Aushon Biosystems, a venture-backed company with a novel multiplex immunoassay platform. She previously served as President, CEO, and a Director of SeraCare Life Sciences, a publicly traded life sciences company focused on human diagnostics and therapeutics. From 2001 to 2005, she served as President of the Biopharmaceutical Division of Millipore Corporation (now MilliporeSigma), where she began her career in 1981. She earned a Master of Business Administration with high honors in Finance from Boston University, where she received a Distinguished Alumni Award in 2009, and a Bachelor of Arts degree from Brown University.
The Company also announced that Steven Wheeler, who has served as a director of Anika since 1993 and currently chairs the Board’s Governance and Nominating Committee, has notified the Board of his intention to retire as of February 8, 2019.
“This is another important step in the transition of Anika’s leadership that began with the appointment of Joseph Darling as CEO in March of this year,” said Joseph L. Bower, Chairman of the Board of Directors, “and it demonstrates our continued commitment to strong corporate governance and refreshment of the Board.”
“Sue brings to Anika more than thirty-five years of experience in the global life science research, pharmaceutical, biotech and clinical diagnostics industries, and we are excited she is joining our Board,” said Joseph G. Darling, President and CEO of Anika. “We are confident that Anika will benefit greatly from her input and guidance as we continue to advance our ongoing initiatives and enhance our global commercial reach.”
“Anika has a strong foundation with a deep pipeline and a diverse commercial portfolio, and I am excited to work with the other directors and management team to continue advancing the Company’s important work. I look forward to leveraging my experience as we continue to advance Anika’s clinical programs, deliver important therapeutic options for patients and drive profitable growth to enhance value for Anika shareholders,” Ms. Vogt said.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic and regenerative medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika's orthopedic medicine portfolio includes ORTHOVISC®, MONOVISC®, and CINGAL®, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.
